GENE ONLINE|News &
Opinion
Blog

2022 psychedelics
Shifting From Counterculture to Clinical Applications, The Problems Psychedelics Face Getting to Market
2022-07-22
Refining Psychedelics into Medicine – An Interview with Doug Drysdale, CEO of Cybin
2022-04-19
The Renaissance of Psychedelics Research: An Interview with the CEO of MindMed, Rob Barrow
2022-04-12
WSJ Health Forum 2022: Psychedelics Set to Take Center Stage in Mental Wellness
2022-03-24
Low Doses of LSD as a Potential Treatment for Anxiety in the Future?
2022-03-22
History on Depression Therapy: the Past and the Psychedelic Future
2022-03-21
Cure or Poison? New Ventures Go IPO Continuously As “Psychedelics” Enter the Mental Health Market
2022-03-09
From Forbidden Drugs to Psychotropic Cures: A “Psychedelic Boom” Breaks New Ground in Treating Mental Illnesses
2022-03-08
LATEST
AstraZeneca Welcomes Neurofibromatosis And Asthma Treatment Approvals in Japan
2022-09-28
Biogen Concludes $900 Million Settlement Before Posting Positive Data From Alzheimer’s Trial
2022-09-28
Arsenal Biosciences Announced Another $70 million Collaboration, This Time With Genentech
2022-09-27
Sciwind Biosciences And SynerK Join Forces To Develop siRNA Therapeutics
2022-09-27
Acticor Enrolls First Patient in Phase 2/3 Stroke Treatment Study
2022-09-27
Daiichi Sankyo Wins Approval For Cancer Treatment in Japan
2022-09-26
Seagen Strikes Potential $650 million Deal with LAVA Therapeutics for Cancer Treatment
2022-09-26
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!